Note 10 - License Agreements (Details Textual) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Jul. 28, 2023	Dec. 31, 2012	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2018	Jan. 31, 2012
Income Tax Expense (Benefit)			$ 2,211	$ 390	$ 0
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred			31,000
Accounts Payable			0
L F B License Agreement [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)							15 years
Royalty Expense			30,700
Accrued Royalties			10,300
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Upfront Fee Received From Sub License		$ 2,000
Income Tax Expense (Benefit)		300
License Revenue			200	200	$ 200
Deferred Revenue			200	300
Additional Amount Receivable on Achievement of Pre-specified Milestones		$ 5,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Commercialization Agreement With Neuraxpharm [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones	$ 480,000
License and Collaboration Agreements, One-time, Non-refundable Payment	140,000			$ 140,000
Additional Payments Upon Key Market Commercial Launch	$ 12,500
Royalty Percentage on Net Product Sales	30.00%
Agreement Buyback Period (Year)	2 years
Commercialization Agreement With Neuraxpharm [Member] | Royalty [Member]
Revenues			$ 800
TG 1701 [Member]
Additional Amount Payable on Achievement of Pre-specified Milestones						$ 350,000